Bio-Path Holdings, Inc. (BPTH)
OTCMKTS · Delayed Price · Currency is USD
0.0620
+0.0020 (3.33%)
At close: Feb 26, 2026
Bio-Path Holdings Employees
Bio-Path Holdings had 10 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
10
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,117,800
Market Cap
579.21K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 10 | 0 | - |
| Dec 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 10 | 0 | - |
| Dec 31, 2021 | 10 | 0 | - |
| Dec 31, 2020 | 10 | 1 | 11.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Scorpius Holdings | 91 |
| Hepion Pharmaceuticals | 22 |
| Windtree Therapeutics | 14 |
| Altamira Therapeutics | 11 |
| Lipella Pharmaceuticals | 7 |
Bio-Path Holdings News
- 9 months ago - Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 - Newsfile Corp
- 9 months ago - Bio-Path Holdings Provides Clinical and Operational Update - GlobeNewsWire
- 10 months ago - Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 - GlobeNewsWire
- 10 months ago - Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 11 months ago - Bio-Path Holdings Reports Full Year 2024 Financial Results - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Provides Key Clinical Updates - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia - GlobeNewsWire